As Per the Report, the Size of the Europe Dendritic Cell Cancer Vaccines Market is valued at USD xx billion in 2019 and is poised to reach USD xx billion by 2024, to grow at a CAGR of xx% during the forecast period 2019-2024.
Leukocytes of a very rare kind are termed as Dendritic cells (DCs). They are highly effective in providing antigens to T cells. If kept isolated and administered tumor antigen ex vivo then DCs if administered as a cellular vaccine are found to enhance immunity in animals. They are found in lymphoid organs. Enhancement in immunity comes from the secretion of cytokines. As of now, cancer treatment relies heavily on radiation, chemo, etc. DCS is adaptable and hence provides flexibility in the treatment of different kinds of cancer.
The increasing number of cases of people suffering from cancer, better availability of treatment methods, rising healthcare expenditure, savory government policies and heavy investments in R&D, and improving success rates of clinical trials are the primary factors driving the growth of this market. Augmenting the geriatric population, rapid advancements in technology and the ability to combat several cancer antigens are the secondary factors fuelling market growth.
Little or no penetration of DC vaccines in remote areas, strict administrative and regulatory frameworks, and ambiguity over the results of the clinical trials on these vaccines are the primary restraints of market growth.
Europe Dendritic Cell Cancer Vaccines Market has been segmented and sub-segmented into the following categories
On the basis of product type, the Provenge was the first DC vaccine which was introduced in the market. So naturally it follows that it is the market leader and is expected to remain so till the end of the forecast period. It treats melanoma, prostate cancer etc. It was approved by the FDA nearly seven years ago.
On the basis of region, Europe is not far behind and is expected to close in on the North American market in the aforementioned forecast period. UK is the market leader in this region.
Prominent Companies leading the Europe Dendritic Cell Cancer Vaccines Market Profiled in the Report are 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation (Dendreon Corporation). Other players in the market include Elios Therapeutics. ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, Merck & co, Northwest Biotherapeutics, Glaxo Smith Kline, ImmunoCellular Therapeutics, Tella Incorporation, and Vaxil BioTherapeutics.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Introduction
5.1.2 CreaVax
5.1.3 Sipuleucel-T (Provenge)
5.1.4 Others
5.1.5 Y-o-Y Growth Analysis, By Product Type
5.1.6 Market Attractiveness Analysis, By Product Type
5.1.7 Market Share Analysis, By Product Type
5.2 End User
5.2.1 Introduction
5.2.2 Pediatrics
5.2.3 Adults
5.2.4 Y-o-Y Growth Analysis, By End User
5.2.5 Market Attractiveness Analysis, By End User
5.2.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product Type
6.1.3.3 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product Type
6.1.4.3 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product Type
6.1.5.3 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
6.7 Rest of Europe
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 3M Company
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Activarti
8.3 Argos Therapeutics
8.4 Batavia Bioservices
8.5 Bellicum Pharmaceuticals
8.6 Creagene
8.7 DanDrit Biotech
8.8 DCPrime
8.9 Sanpower Corporation (Dendreon Corporation)
8.10 Elios Therapeutics
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
